Apomorphine Injection and Relugolix: Interaction Details

Brand names
Apomorphine Injection
ApokynOnapgo
Relugolix
Orgovyx
Same medicines, other forms
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page

A close look at the Apomorphine Injection and Relugolix interaction:

Share

Share this interaction

What Happens When You Take Apomorphine Injection With Relugolix

What can happen when they are taken together (rated Major)

Increased risk of

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

Using relugolix together with other drugs that prolong the produces QT effects. Androgen deprivation from GnRH or can itself lengthen the QT interval.

In patients with congenital long QT syndrome, congestive heart failure, or frequent electrolyte abnormalities, and in those receiving drugs known to prolong the QT interval, weigh whether the benefits of androgen deprivation therapy such as relugolix exceed the possible risks.3 Where possible, avoid combining relugolix with agents that prolong QT. When cannot be avoided, do not use drugs that cause electrolyte disturbances (ie, or ),1 correct any electrolyte abnormalities, and consider periodic and electrolyte monitoring.3

The Apomorphine Injection and Relugolix Interaction, Explained

Both apomorphine (used for "off" episodes in Parkinson's disease) and relugolix (used for advanced prostate cancer) can affect the heart's electrical rhythm, a measurement called the . Taking them together may add up this effect. This is based on how the drugs work, not on proven cases, so it is a theoretical concern.

A longer QT interval can sometimes lead to a fast, irregular heartbeat. Please keep taking both as prescribed, and tell your care team about any heart rhythm problems, fainting, or dizziness. They can check your heart tracing () and blood minerals like potassium and magnesium, and tailor your plan to keep you safe.

(), theoretical evidence, major severity, onset unspecified.

  • Androgen deprivation (GnRH such as relugolix) may prolong ; apomorphine is also associated with QT prolongation. No PK interaction is implied.
  • Risk is greater with congenital long QT, heart failure, or electrolyte abnormalities.
  • Management: weigh ADT benefit against risk, avoid combining with QT-prolonging agents when possible. If is required, avoid agents causing or , correct electrolytes, and consider periodic and electrolyte monitoring.

See the 3 references behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Apomorphine Injection and Relugolix Interact

The likely mechanism

In short: Apomorphine injection and relugolix both lengthen the QT interval, a measure of the heart’s rhythm, so taken together the effect can add up.
How Drug Interactions Work See this kind of interaction drawn out, step by step, in “When Effects Add Up or Cancel Out”, one chapter of our one-minute explainer. See how it works 

How to Manage the Apomorphine Injection and Relugolix Interaction

Your care team will first weigh whether the benefits of relugolix outweigh the risks for you, and they may prefer to avoid pairing QT-prolonging medicines when possible. If you need both, they can tailor the plan to you.

  • Keep taking both medicines as prescribed unless told otherwise.
  • Your team may avoid medicines that lower potassium or magnesium and correct any low levels.
  • They may monitor you more closely with periodic ECGs and blood tests for electrolytes.
  • Tell your pharmacist or prescriber about any heart conditions, including long QT syndrome or heart failure, and about all your other medicines.
  • Report fainting, palpitations, or a racing heartbeat promptly.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Apomorphine Injection or Relugolix need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

1 report from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes

    A study of male patients receiving androgen deprivation therapy (ADT) analyzed individual case safety reports from the international pharmacovigilance database VigiBase and identified 184 cases of acquired long-QT syndrome (aLQTS) and/or (TdP; 11% fatal) and 99 cases of sudden death associated with ADT. Most aLQTS/TdP cases (62%) and sudden death cases (88%) associated with ADT occurred without exposure to other drugs known to raise TdP risk.

    However, exposure to 1 drug and to 2 or more drugs with conditional, possible, or known TdP risk was reported in some aLQTS/TdP events (23% and 43%, respectively) and sudden death events (18% and 22%, respectively). The drugs classed as ADTs were abiraterone, gonadotropin-releasing hormone and , nonsteroidal androgen receptor indicated for prostate cancer, and 5-alpha-reductase inhibitors indicated for androgenic alopecia and prostatism.

    Among the 10 ADTs evaluated, 7 showed a disproportionate association (reporting odds ratio, 1.4 to 4.7) with aLQTS, TdP, or sudden death: leuprorelin, goserelin, triptorelin, degarelix, bicalutamide, finasteride, and dutasteride. The median patient age was about 76 years.

    The median time to onset was 170 days (range, 7 to 4884 days) for aLQTS/TdP events and 92 days (range, 0.25 to 4984 days) for sudden death events. Patients received ADT mainly for prostate cancer, and some received it for prostatism and androgenic alopecia. Most patients were on ADT monotherapy (83%), while 17% received ADT combination therapy.2

Apomorphine Injection and Relugolix: Common Questions

How serious is the Apomorphine Injection and Relugolix interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Apomorphine Injection and Relugolix interaction managed?

Your care team will first weigh whether the benefits of relugolix outweigh the risks for you, and they may prefer to avoid pairing QT-prolonging medicines when possible. If you need both, they can tailor the plan to you. Keep taking both medicines as prescribed unless told otherwise. Your team may avoid medicines that lower potassium or magnesium and correct any low levels. They may monitor you mo… Management is individual — always follow your own care team's guidance.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

Ask About the Apomorphine Injection and Relugolix Interaction

Ask in your own words about taking Apomorphine Injection and Relugolix together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (3)

  1. Lyon AR, Lopez-Fernandez T, Couch LS, et al: 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43(41):4229-4361.
  2. Salem JE, Yang T, Moslehi JJ, et al: Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Circulation 2019; 140(13):1070-1080. PubMed
  3. Product Information: ORGOVYX oral tablets, relugolix oral tablets. Sumitomo Pharma America, Inc (per FDA), Marlborough, MA, 2025.
Was this write-up helpful?

Other Serious Interactions of Apomorphine Injection and Relugolix

Also serious with Apomorphine Injection

Also serious with Relugolix

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Relugolix

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, as soon as they can.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.